Colchicine in cardiovascular disease

Cardiac rehabilitation delivered at home or through digital tools.

Key point: Exercise-based telerehabilitation probably improves cardiorespiratory fitness in adults with CVD but provides no convincing evidence of an antihypertensive effect.

An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.

Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.

A newer class of anticoagulants that target factor XI or XIa.

Key point: Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.

A catheter procedure targeting renal nerves to lower blood pressure.

Shockwaves delivered through a balloon catheter to crack calcium in arteries.

New blood pressure drugs, including aldosterone synthase inhibitors and zilebesiran.

Key point: Aldosterone-targeted therapies, including aldosterone-synthase inhibitors and spironolactone, provide clinically meaningful systolic blood pressure reductions in resistant hypertension without increasing serious adverse events.